Polaris Capital Management LLC Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Polaris Capital Management LLC reduced its stake in Jazz Pharmaceuticals by 27.9%, selling 245,000 shares and maintaining around 4.5% of its portfolio in the company.
• Jazz Pharmaceuticals reported a quarterly earnings miss, with an EPS of ($8.25) compared to estimates of ($5.61), despite a revenue increase of 2.1% year-over-year.
• Various research firms recently issued mixed ratings for Jazz Pharmaceuticals, with a consensus average price target of $178.93 and the stock earning a rating of "Moderate Buy."

Polaris Capital Management LLC lessened its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 27.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 634,160 shares of the specialty pharmaceutical company's stock after selling 245,000 shares during the period. Jazz Pharmaceuticals accounts for about 4.5% of Polaris Capital Management LLC's portfolio, making the stock its 5th largest position. Polaris Capital Management LLC owned 1.05% of Jazz Pharmaceuticals worth $67,297,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JAZZ. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals in the first quarter valued at about $25,000. Parallel Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares during the last quarter. Picton Mahoney Asset Management boosted its holdings in Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. Spire Wealth Management boosted its holdings in Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after acquiring an additional 161 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in Jazz Pharmaceuticals in the first quarter valued at about $36,000. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $139.48 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market capitalization of $8.46 billion, a P/E ratio of -20.73, a price-to-earnings-growth ratio of 8.51 and a beta of 0.28. The stock has a fifty day moving average of $123.75 and a 200-day moving average of $115.84.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the firm posted $5.30 EPS. Jazz Pharmaceuticals's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JAZZ. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Weiss Ratings reissued a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research note on Saturday, September 27th. Morgan Stanley increased their target price on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research note on Wednesday, September 24th. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Finally, Truist Financial increased their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $178.93.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.